Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes

NCT06559722 is registered in ClinicalTrials.gov with Tonghua Dongbao Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT06559722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06559722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 31, 2024
Completion date
February 28, 2026
Enrollment
510 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes